Overview | Day 1 | Day 2 | Download Brochure

MAIN CONFERENCE

WEDNESDAY, FEBRUARY 25

7:15am Registration Open and Morning Coffee

8:45 Plenary Keynote Introduction 
Kathryn Lowell, Deputy Secretary, Life Sciences, California Business Transportation & Housing Agency

8:55       Plenary Keynote 1
Therapy Development in a Networked World
Jay M. Tenenbaum, Ph.D., Chairman and Chief Scientist, CollabRx, Inc.
A new paradigm for translational research will be described that combines the integrative and collaborative power of the Internet with personalized molecular analysis to slash the time and cost of therapy development. A key element is the creation of Health Commons, an open web-based ecosystem of researchers, clinicians, patients, pharma/biotechs, and service/technology providers that can be rapidly mobilized to develop targeted therapies for disease subclasses. This ecosystem will stimulate the same radical increase in efficiency for therapy development that ecommerce brought to business in the 1990s, ushering in a new age of collaborative, personalized medicine where every patient can afford custom therapies and discovery is driven by collectively interpreting the outcomes across all patients.

9:40 Grand Opening Refreshment Break in the Exhibit Hall

LEADING THROUGH DISRUPTION AND TRANSFORMATION

11:00 Executive Summit Chairperson’s Remarks
Bill W. Massey, Ph.D., President, LITMUS Molecular Design LLC

11:10 Competing in the Dynamic Economy of the 21st Century: Challenges and Opportunities
Bill W. Massey, Ph.D., President, LITMUS Molecular Design LLC
Through case analysis, application exercises, and interactive breakout discussions, participants will examine innovation and leadership during transformation change. Learn leadership skills to help you leverage opportunities, design effective strategies, and drive implementation for diversifying product/service portfolios, expanding R&D investments in emerging markets, developing new partner/alliance/collaboration models, and implementing novel approaches towards product commercialization. 

11:40 Inventing New Ways to Think About IP: Time for an IP Share Market?
James Lyons-Weiler, Ph.D., Director, Bioinformatics Analysis Core, University of Pittsburgh; Adjunct Faculty, Department of Biomedical Informatics
Direct investment in market-valued intellectual property could drive forward translational success. It is time for revolutionary IP models to transform our global econo-my. Thousands of potentially life-saving and life-changing ideas, such as orphan drugs, exist scattered across Pharma. The biotechnology and pharmaceutical sectors would be a wonderfully humane place to test and ground-truth the concept, and would serve as a model for all IP-rich technology sectors, generating wealth and placing it in the hands of individuals with the ideas and visions to drive their programs forward, and securing a healthier future for us all. Attendees will explore this concept further as well as the advantages of direct investment to investors and organizations. 

12:10pm Case Study: Adapting an Organization to Focus on Innovation & IP Management
Jochen Hurlebaus, Ph.D., M.B.A., Director, Innovation and IP Management, Roche Diagnostics GmbH
Within Roche Professional Diagnostics, we have implemented in the last two years new strategies for innovation and IP management. The technological development and IP strategy is based on identification of long term trends in society, markets and technology. All developments, even early technological developments, require a joint effort between business and R&D representatives in order to be funded. This approach required organizational and process changes within Roche Diagnostics which will be presented. The case shows how Roche Diagnostics has changed in order to foster innovation and ensure future success.

DIVERSIFYING PRODUCT/SERVICE PORTFOLIOS

12:40 Case Study: Drug Repurposing Strategy: Extending the Life of Blockbuster Products with Synergistic Repurposed-drug Combinations
John Maki, President and Chief Executive Officer, Vicus Therapeutics
Over $100 billion worth of blockbuster product sales will be going off-patent and thus subject to generic incursion between 2008-2012. Vicus Therapeutics is leveraging this market trend with drug repurposing to discover and develop novel, high-impact drugs for critical unmet clinical needs in the cancer arena. Drug repurposing is becoming an attractive business strategy. It reduces risks and costs and creates opportunities to fill pipelines with new products that have a higher level of success, an accelerated development timeframe, and a quicker FDA approval process. Repurposing a drug from outside a therapeutic area and combining the drug with a blockbuster offers the potential to add significant and proprietary clinical value beyond that provided by the blockbuster drug alone. This session reviews case study examples and benefits of synergistic, repurposed-drug combinations and discusses methods for identifying and developing such product candidates.

1:10 Networking Luncheon in the Tri-Conference Exhibit Hall

2:15 Executive Summit Chairperson’s Remarks

2:20 Case Study: NanoMedicine: Next Generation Blockbusters 
Arkesh Mehta, Ph.D., Founder & CEO, Chikujee Therapeutics
Chikujee Therapeutics utilizes nanomedicine as an innovative multifunctional NanoBindi technology to build a portfolio of potentially safer and more effective versions of well-known anti-cancer agents. The company employs several platform technologies that utilize new chemical entities, generic drugs, or existing drug types ranging from small synthetic molecules to large recombinant macromolecules. This session reviews Chikujee’s business strategy of generics to brand, life cycle extension, and new drugs by IP unlocking. Attendees will learn how to establish and maintain competitive advantage without excessive R&D expense and low development expense with high probability of regulatory agency approval.

2:50 Innovations and Optimizations of Antibody Therapeutics
Bruce Keyt, Ph.D., Vice President Research and Chief Technology Officer, Trellis Bioscience, Inc.
One of the fastest growing segments of the pharmaceutical market is therapeutic antibodies. The past five years have seen an approximate triple in value. This talk will discuss how evolutions in innovation and business model dynamics need to continue driving the sector’s position and how life sciences organizations can best achieve this. We will explore the movement of antibody technologies towards fully human products (as opposed to chimeric products) and the role of safety of biologicals. Attendees will learn how to identify opportunities to effectively plan product and technology licensing strategies.

3:20 Case Study: Diversification of Product Portfolio 
Mauri Okamoto-Kearney, Vice President, Product Development & New Product Planning, KAI Pharmaceuticals, Inc.
With increasing pressures for viable exit strategies, private biopharma companies require diversification strategies for their product portfolios to add perceived and real value. KAI Pharmaceuticals uses risk estimates, resource needs, timeline, and value assessments to define interim financial gates to move products through its pipeline. This presentation discusses some of these diversification strategies and how market opportunity assessments and longer term goals of commercialization and revenue generation are linked to business and corporate development strategies.

3:50 Executive Summit De-brief
Program Chair will lead an interactive discussion with participants on the knowledge and ideas they have gleaned throughout the day and how they can be applied to your working environment.

4:20 Reception in the Exhibit Hall

5:00 Breakout Discussions in the Exhibit Hall

6:00 Close of Day

Overview | Day 1 | Day 2 | Download Brochure

For questions or suggestions about the meeting, please contact:
Cindy Crowninshield
Cambridge Healthtech Institute
Tel: 781-354-0120
email: ccrowninshield@healthtech.com

For sponsorship and exhibit sales information, please contact:
Arnold Wolfson
Cambridge Healthtech Institute
Phone: 781-972-5431
Email: awolfson@healthtech.com